In the latest echocardiographic assessment, 88.3% presented with mild AR or better. Freedom from reoperation at 8 years was 95.4%. There was no case of endocarditis and one patient had a stroke 2 years after the operation. There were no between-group differences in morbidity, mortality and complications during the follow-up.
VSARR can be performed with low mortality rates and reasonable durability of the aortic valve. Neither moderate or severe AR nor the need for aortic valve repair during the procedure altered survival and freedom from reoperation.
VSARR can be performed with low mortality rates and reasonable durability of the aortic valve. Neither moderate or severe AR nor the need for aortic valve repair during the procedure altered survival and freedom from reoperation.Risk stratifying candidates for left ventricular assist device (LVAD) is challenging. While INTERMACS profiles provide some prognostic insights, there is an ongoing search for better tools. We studied pre-LVAD haemodynamic parameters in predicting post-LVAD mortality.
We analysed the INTERMACS dataset for the ability of right atrial pressure (RAP), pulmonary capillary wedge pressure (PCWP), pulmonary arterial systolic (PASP) and diastolic pressures (PADP), mean pulmonary artery pressure, transpulmonary gradient, cardiac output, cardiac power output and INTERMACS profiles, all recorded before LVAD implantation, to predict mortality.
Among 18,733 patients in the INTERMACS dataset, we found that, RAP was the main significant haemodynamic predictor of mortality (13.1 vs. https://www.selleckchem.com/products/ot-82.html 14.4 mmHg in survivors and non-survivors, respectively, p&lt;0.001), and a higher RAP also predicted the need for extra-corporeal membrane oxygenation (ECMO) support (p&lt;0.001) and intra-aortic balloon pump (p&lt;0.001). Right atrial presn general, haemodynamic variables, as well as other criteria including INTERMACS profiles, are weak predictors of mortality. Right atrial pressure is the main consistent haemodynamic predictor of mortality in LVAD recipients. It outperforms other haemodynamic parameters, and keeps its value within each INTERMACS profile.
In general, haemodynamic variables, as well as other criteria including INTERMACS profiles, are weak predictors of mortality. Right atrial pressure is the main consistent haemodynamic predictor of mortality in LVAD recipients. It outperforms other haemodynamic parameters, and keeps its value within each INTERMACS profile.The ideal prosthesis for tricuspid valve replacement (TVR) continues to be debated. There are few published data comparing mechanical and bioprosthetic valves, and all are retrospective studies with relatively small sample sizes.
This study was conducted to compare mechanical and bioprosthetic valves for TVR.
A literature search of six databases (PubMed, EMBASE, Ovid, ScienceDirect, JSTOR, and Wiley Blackwell's online library) was performed with the keywords "tricuspid valve disease, tricuspid valve replacement and (bioprosthetic or mechanical)". Primary outcomes were hospital mortality, long-term survival, tricuspid valve reoperation, valve failure, thrombosis, and thrombo-embolism. Risk ratio (RR) was used to compare dichotomous parameters and time-to-event outcomes. "Survival and re-interventions" were pooled using a meta-analysis of hazard ratios (HR). Publication bias was accessed using a funnel plot.
A total of 23 retrospective studies involving 945 mechanical and 1,332 biological tricuspid prososition should depend mainly on the patient's risk factors and no superiority of one prosthesis over the other in this position.
The results of this meta-analysis suggest an equal risk of 30-day and late mortality, reoperation, and 5-year valve failure in patients with mechanical versus biological TVR. The choice of the prosthesis in the tricuspid position should depend mainly on the patient's risk factors and no superiority of one prosthesis over the other in this position.BRCA1/2 mutation carriers are generally exposed to early menopause due to risk-reducing salpingo-oophorectomy (RRSO) around the age of 40 years. This risk-reducing intervention is based on a 10-40% life-time risk of ovarian cancer in this population. Although effective, premature and acute menopause induces non-cancer related morbidity in both the short and long term. Little is known about the impact of RRSO on the cardiovascular system.
This cross-sectional study explored the relationship between time since RRSO and signs of subclinical atherosclerosis, as measured by carotid intima-media thickness (CIMT) and pulse wave velocity (PWV), in 165 BRCA1/2 mutation carriers. All participants, aged 40 to 63 years, underwent RRSO before the age of 45 years, and at least 5 years ago. Cardiovascular risk factors were assessed by questionnaires and a single screening visit. Data were analyzed using linear regression models.
Mean CIMT was 692.7μm (SD 87.0), and mean central PWV 6.40m/s (SD 1.42). After adjustment for age and several relevant cardiovascular risk factors, time since RRSO was not associated with CIMT (β=0.68μm; 95% CI -4.02, 5.38) and PWV (β=44mm/s; 95% CI -32, 120). Compared to women of a reference group from the general population, lower systolic blood pressure [mean difference 12mmHg; 95% confidence interval (CI) 10, 14] was found in BRCA1/2 mutation carriers.
We found that, in BRCA1/2 mutation carriers, at 5 to 24 years follow-up, time since RRSO is not related to development of subclinical atherosclerosis. However, the follow-up period in these relatively young women might have been too short.
We found that, in BRCA1/2 mutation carriers, at 5 to 24 years follow-up, time since RRSO is not related to development of subclinical atherosclerosis. However, the follow-up period in these relatively young women might have been too short.Endovascular treatment (EVT) for femoropopliteal artery disease is common in clinical practice. However, little is known about its prognostic factors, causes of death, and long-term clinical outcomes.
Two hundred eighty-five consecutive patients (mean age, 72±8 years, 73% men) undergoing their first EVT for de-novo femoropopliteal artery disease from 2009 to 2018 were studied. Patients were divided in two groups according to the presence of critical limb ischemia (CLI). We evaluated the incidence of major adverse limb events (MALE) including clinically driven target vessel revascularization and target limb major amputation, and all-cause death.
The procedure was successful in 97.9% of cases. The non-CLI group comprised 205 patients (72%), and the CLI group comprised 80 patients (28%). The CLI group exhibited higher high-sensitivity C-reactive protein (hs-CRP) levels and a higher rate of hemodialysis than the non-CLI group. During the median follow-up period of 3.5 years, there were 62 deaths (21.8%) including cardiovascular (32.